Cargando…
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
To date, there are no clinically effective neuroprotective or disease-modifying treatments that can halt Parkinson's disease (PD) progression. The current clinical approach focuses on symptomatic management. This failure may relate to the complex neurobiology underpinning the development of PD...
Autores principales: | Sportelli, Carolina, Urso, Daniele, Jenner, Peter, Chaudhuri, K. Ray |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304367/ https://www.ncbi.nlm.nih.gov/pubmed/32595595 http://dx.doi.org/10.3389/fneur.2020.00556 |
Ejemplares similares
-
Editorial: Prodromal Parkinson's Disease
por: Crosiers, David, et al.
Publicado: (2021) -
Clinical and Imaging Markers of Prodromal Parkinson's Disease
por: Hustad, Eldbjørg, et al.
Publicado: (2020) -
Prodromal Markers of Parkinson's Disease in Patients With Essential Tremor
por: Wang, Xi-Xi, et al.
Publicado: (2020) -
Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease
por: De Groote, Evelien, et al.
Publicado: (2020) -
Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective
por: Vermeiren, Yannick, et al.
Publicado: (2020)